Literature DB >> 570658

Methylphenidate-induced chorea: case report and pharmacologic implications.

W J Weiner, P A Nausieda, H L Klawans.   

Abstract

In a child with minimal brain dysfunction, we found that chorea was related to the major central effect of methylphenidate and probably to the effect of the drug on central catecholaminergic systems. Also, after 3 weeks of treatment with methylphenidate, guinea pigs showed a hypersensitive response to apomorphine, suggesting that chronic administration of methylphenidate leads to hypersensitivity of receptor sites. Chorea beginning shortly after initiation of methylphenidate therapy probably is related to the central dopaminergic effect of the drug; when choreic movements appear after chronic methylphenidate administration, altered responsiveness of striatal dopamine receptor sites may be responsible.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 570658     DOI: 10.1212/wnl.28.10.1041

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  Methylphenidate-induced akathisia in a patient with multiple sclerosis.

Authors:  Maria S Almeida; Prasad R Padala; Subhash Bhatia
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

2.  d-Amphetamine-induced "floating limb" syndrome in young rhesus monkeys.

Authors:  E D Levin; P J Bushnell; C M Baysinger
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 4.  Differential diagnosis of chorea.

Authors:  Ruth H Walker
Journal:  Curr Neurol Neurosci Rep       Date:  2011-08       Impact factor: 5.081

5.  Dyskinesias possibly induced by norpseudoephedrine.

Authors:  A Thiel; D Dressler
Journal:  J Neurol       Date:  1994-01       Impact factor: 4.849

6.  Methylphenidate-induced Exacerbation of Chorea in a Child Resolved with Switching to Atomoxetine.

Authors:  Ozalp Ekinci; Cemre Yaşöz; Selin Ayşe İpek Baş; Nazan Ekinci; Özge İpek Doğan
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-05-31       Impact factor: 2.582

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.